吸入氧化治疗是有效的改善右心室功能在接受ECPELLA支持的患者
Yusuke Motoji1, Tadashi Kitamura2, Toshiaki Mishima2
1Department of Cardiovascular Surgery, Kitasato University School of Medicine, Kanagawa, Japan. ymotoji1031@gmail.com.
General thoracic and cardiovascular surgery
|July 20, 2025
概括
吸入的氧化 (iNO) 治疗改善了ECPELLA (用Impella进行静脉外体膜氧化) 的患者的右心室和左心室功能. 然而,对iNO无反应的严重右心室功能障碍显示出不良结果.
科学领域:
- 心脏病学 心脏病学
- 关键护理医学 关键护理医学
- 心血管外科心血管外科
背景情况:
- ECPELLA (带有Impella的静脉外体膜氧化) 用于心脏性休克.
- 患有严重右心功能障碍的患者往往很难从V-A ECMO中断奶.
- 吸入的氧化 (iNO) 可以通过调节肺动脉压力来改善右心室功能.
研究的目的:
- 为了评估iNO对ECPELLA支持的患者右心室和左心室功能的影响.
- 为了确定iNO是否能改善ECPELLA治疗心脏性休克患者的血液动力学参数.
主要方法:
- 对16名ECPELLA支持的心脏性休克患者的回顾性分析,这些患者接受iNO治疗右心衰竭.
- 当肺动脉脉动率指数 (PAPi) < 1.0.0 时,iNO 在 20 ppm 开始.
- 在iNO启动前和24小时后进行的血液动力学测量 (PAPi,RVFAC,CPO,LVEF).
主要成果:
- iNO治疗显著改善了PAPi,右心室分数面积变化 (RVFAC),心脏功率输出 (CPO) 和左心室射出分数 (LVEF).
- 冲动流量增加,而V-A ECMO流量在iNO后减少.
- 成功的ECPELLA断奶发生在75%的患者中;30天死亡率为38%.
结论:
- 在ECPELLA支持的患者中,iNO显著提高了右心室和左心室的功能.
- 右心室功能障碍对iNO的反应失败与ECPELLA患者的不良结果有关.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
316
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
316
Mechanical Ventilation III: Noninvasive Ventilation
224
Noninvasive positive-pressure ventilation (NIPPV), continuous positive airway pressure (CPAP), and bilevel positive airway pressure (BiPAP) are essential methods in respiratory care. These ventilation techniques offer unique benefits for patients with various respiratory conditions, providing adequate support without requiring intubation. Let's explore how each method is crucial in improving patient outcomes and enhancing respiratory therapy.
Noninvasive Positive-Pressure Ventilation...
Noninvasive Positive-Pressure Ventilation...
224
Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
223
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
246
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
246


